News Year: - Any -20212020201920182017201620152014201320122011201020092008 Date Title and Summary Additional Formats Toggle SummaryJun 05, 2008 Sinexus Welcomes New CEO and Completes Series B Sinexus Welcomes New CEO and Completes Series B 16.5 KB Toggle SummaryJan 07, 2010 Sinexus changes name to Intersect ENT, Initiates Pivotal Study Sinexus changes name to Intersect ENT, Initiates Pivotal Study 63.5 KB Toggle SummaryNov 01, 2010 Intersect ENT Closes Series C Financing, Recognized for Clinical Science Intersect ENT Closes Series C Financing, Recognized for Clinical Science 14.6 KB Toggle SummaryAug 15, 2011 Intersect ENT Announces U.S. Food and Drug Administration Approval for First Drug Releasing Implant for Chronic Sinusitis Patients Intersect ENT Announces U.S. Food and Drug Administration Approval for First Drug Releasing Implant for Chronic Sinusitis Patients 116.9 KB Toggle SummarySep 13, 2011 Intersect ENT Announces Positive Data from Pivotal Study of Propel Implant, Showing Significantly Improved Outcomes For Sinus Surgery Intersect ENT Announces Positive Data from Pivotal Study of Propel Implant, Showing Significantly Improved Outcomes For Sinus Surgery 176.4 KB Toggle SummaryApr 17, 2012 Intersect ENT Quadruples Operation Size with Expansion to New Facility in Menlo Park, Calif. IntersectENT_PressRelease-Quadruples_Operation_Size_2012_04_17.pdf 148.4 KB Toggle SummaryJun 06, 2012 Groundbreaking Clinical Evidence Demonstrates Benefit of PROPEL Implant for Chronic Sinusitis Patients Groundbreaking Clinical Evidence Demonstrates Benefit of PROPEL Implant for Chronic Sinusitis Patients 172.7 KB Toggle SummaryNov 06, 2012 Intersect ENT Announces FDA Approval of New Steroid-Releasing Implant, Allowing More Chronic Sinusitis Patients to Benefit from Localized Drug Delivery Intersect ENT Announces FDA Approval of New Steroid-Releasing Implant, Allowing More Chronic Sinusitis Patients to Benefit from Localized Drug Delivery 32.6 KB Toggle SummaryJan 31, 2013 Intersect ENT Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients Intersect ENT Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients 89.4 KB Toggle SummaryFeb 25, 2013 Intersect ENT Raises $30 Million Funds to Fuel Commercial Expansion and Development of Next Generation Products for Chronic Sinusitis Sufferers Intersect ENT Raises $30 Million Funds to Fuel Commercial Expansion and Development of Next Generation Products for Chronic Sinusitis Sufferers 32.4 KB Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
Intersect ENT Announces U.S. Food and Drug Administration Approval for First Drug Releasing Implant for Chronic Sinusitis Patients 116.9 KB
Intersect ENT Announces Positive Data from Pivotal Study of Propel Implant, Showing Significantly Improved Outcomes For Sinus Surgery 176.4 KB
Groundbreaking Clinical Evidence Demonstrates Benefit of PROPEL Implant for Chronic Sinusitis Patients 172.7 KB
Intersect ENT Announces FDA Approval of New Steroid-Releasing Implant, Allowing More Chronic Sinusitis Patients to Benefit from Localized Drug Delivery 32.6 KB
Intersect ENT Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients 89.4 KB
Intersect ENT Raises $30 Million Funds to Fuel Commercial Expansion and Development of Next Generation Products for Chronic Sinusitis Sufferers 32.4 KB
